ALKERMES | ALKS - Loan Capital


ALKERMES reported $285.82M in Loan Capital for its fiscal quarter ending in September of 2024.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Acadia Pharmaceuticals USD 0 0 Mar/2025
ALKERMES USD 285.82M 639K Sep/2024
Amgen USD 50B 2.43B Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Coherus Biosciences USD 294.85M 2.33M Mar/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Gilead Sciences USD 22.14B 5M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 28.78M 596.71M Sep/2025
J&J USD 39.44B 30M Dec/2025
Malin Corporation EUR 0 0 Dec/2024
Merck USD 39.97B 6B Sep/2025
Minerva Neurosciences USD 0 86.58M Sep/2024
Nektar Therapeutics USD 107.51M 10.35M Jun/2024
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Otsuka Holdings JPY 166.92B 6.35B Dec/2025
Ovoca Bio EUR 0 0 Jun/2021
Pfizer USD 57.41B 93M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025